The FDA has eased restrictions to the anti-hyperglycemic drug rosiglitazone (Avandia). Patients and healthcare providers will no longer need to register for the rosiglitazone Risk Evaluation and Mitigation Strategy (REMS) program which was required by the FDA in 2010 and the use of Avandia will not be limited to certain patients. This decision follows the re-evaluation of the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) trial which found that Avandia’s heart risks are not greater than other anti-hyperglycemic medications. How comfortable are you dispensing this medication following this announcement?

For more information please click here